GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study: GI Signals

IBD retrospective · n=300 · Aug 21, 2026 · Inflamm Bowel Dis · IF 4.5

GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.

New evidenceulcerative colitis

Clinical takeawayThis observational, single-center finding is insufficient to change UC management. Potential confounding by indication cannot be fully excluded from a retrospective cohort design, despite matching on baseline characteristics. Do not prescribe GLP-1 RAs for UC based on this evidence; prospective randomized trials are needed.

What it foundIn UC patients initiated on GLP-1 RAs (liraglutide or semaglutide) for metabolic indications, symptomatic remission (partial Mayo score ≤2 with rectal bleeding subscore 0) was achieved in 66.7% at 12 weeks versus 25.3% of matched controls; adjusted OR 5.90 (95% CI 3.52-9.86).

ContextGLP-1 RAs are established for metabolic disease (diabetes, obesity) but not for inflammatory bowel disease. This unexpected signal in UC suggests anti-inflammatory effects outside the metabolic pathway, though temporal association does not establish causation. The finding challenges prior assumptions that metabolic agents lack direct GI benefit.

Emergingsuggested applicable standard· American Society of Anesthesiologists, 'Practice Advisory for the Perioperative Management of Patients with Diabetes Mellitus Including Those Taking GLP-1 Receptor Agonists,' 2023

Decision at stakeWhether pre-initiation GI evaluation or specialist clearance is needed before starting GLP-1RA for metabolic indications in patients with ulcerative colitis

… The document does not address whether a GI condition warrants pre-initiation 'GI clearance' before starting a GLP-1RA; that question is not covered by this or any GI society guideline.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perioperative management of a patient already taking a GLP-1 receptor agonist should be individualized through shared decision-making among the patient, the prescribing team, the proceduralist/surgeon, and the anesthesiologist, balancing metabolic need against aspiration risk from delayed gastric emptying. In patients WITHOUT known risk factors for delayed gastric emptying (e.g., pre-existing gastroparesis, diabetes mellitus with neuropathy, prior gastric surgery, or severe GERD), GLP-1RA therapy may be continued preoperatively. When holding is elected, hold the day-of-procedure dose for daily formulations and the dose one week before the procedure for weekly formulations, while acknowledging the guidance states the optimal hold duration is unknown. Regardless of hold status, assess every patient on the day of the procedure for symptoms of delayed gastric emptying (nausea, vomiting, abdominal pain, dyspepsia, distension); if present, manage the patient as a 'full stomach.' For patients WITH known risk factors for delayed gastric emptying, risk-mitigation options include a preoperative clear-liquid diet for at least 24 hours (as in colonoscopy/bariatric prep), point-of-care gastric ultrasound to assess residual gastric contents (limited by resources, inter-user variability, and credentialing), and consideration of rapid-sequence induction versus procedure deferral. The guidance explicitly cautions against reflexively withholding GLP-1RAs only in patients treated for overweight/obesity, which could constitute weight bias. The document does not address whether a GI condition warrants pre-initiation 'GI clearance' before starting a GLP-1RA; that question is not covered by this or any GI society guideline.

American Society of Anesthesiologists, 'Practice Advisory for the Perioperative Management of Patients with Diabetes Mellitus Including Those Taking GLP-1 Receptor Agonists,' 2023 · reviewed 2026-07-21 ↗

Alqinai B … Hadam-Veverka J · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink